Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU was delisted on the 26th of April, 2023.
37 hedge funds and large institutions have $90.4M invested in Eucrates Biomedical Acquisition Corp. Unit in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$10.2M |
| 2 |
BlackRock
New York
|
+$9.39M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.79M |
| 4 |
6CM
683 Capital Management
New York
|
+$6.09M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$5.08M |
Top Sellers
EUCRU Hedge Fund Activity: Q4 2020 in Review
37 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q4 2020, worth a combined $90.4M.
Buyers outnumbered sellers: 37 funds opened new EUCRU positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $10.2M.
- 37 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $90.4M of Eucrates Biomedical Acquisition Corp. Unit stock for Q4 2020.
- 37 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q4 2020 and 0 closed out, a net change of +37 holders.
- The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q4 2020 was Deerfield Management, an estimated $10.2M added.
Based on aggregated 13F filings for Q4 2020.